|Bid||86.00 x 100|
|Ask||138.00 x 200|
|Day's Range||126.20 - 133.66|
|52 Week Range||83.26 - 192.94|
|PE Ratio (TTM)||-14.87|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Waltham-based Tesaro is capitalizing on the early success of its new cancer drug, handing over some development and commercial rights to Takeda in a deal worth up to $340 million plus royalties. Tesaro (TSRO) said Thursday that the once-daily pill, which is marketed in the U.S. as Zejula following an FDA approval in March, will be developed and sold by Takeda in Japan, where the drug giant is headquartered. Under the deal, Takeda will get development and commercial rights in four additional countries — South Korea, Taiwan, Russia and Australia — for all kinds of tumors except prostate cancer.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to TESARO, Inc. Here are 5 ETFs with the largest exposure to TSRO-US. Comparing the performance and risk of TESARO, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
Despite a positive day for the markets, these stocks fell. Find out why.